from Medscape. You may have to register to view:
http://www.medscape.com/viewarticle/572995
The key finding:
"What was most surprising in this study was that patients with low-HER2/
neu-expressing tumors responded so well to the vaccine. In fact, Dr. Benavides pointed out, the patients with low-expressing (0 to 2+ on immunohistochemistry [IHC]) HER2/
neu tumors had a better response to the vaccine than women with higher-expressing tumors. They experienced not only a better immune response, but a better clinical one as well, as demonstrated by a decreased rate of breast cancer recurrence and 0% mortality after E75 peptide vaccination."
Hopeful